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Abstract
Avian influenza virus (H5N1) has caused serious infections in human beings. This virus has the potential to emerge as a
pandemic threat in humans. Effective vaccines against H5N1 virus are needed. A recombinant Bombyx mori baculovirus,
Bmg64HA, was constructed for the expression of HA protein of H5N1 influenza virus displaying on the viral envelope
surface. The HA protein accounted for approximately 3% of the total viral proteins in silkworm pupae infected with the
recombinant virus. Using a series of separation and purification methods, pure Bmgp64HA virus was isolated from these
silkworm pupae bioreactors. Aluminum hydroxide adjuvant was used for an H5N1 influenza vaccine. Immunization with this
vaccine at doses of 2 mg/kg and 0.67 mg/kg was carried out to induce the production of neutralizing antibodies, which
protected monkeys against influenza virus infection. At these doses, the vaccine induced 1:40 antibody titers in 50% and
67% of the monkeys, respectively. The results of safety evaluation indicated that the vaccine did not cause any toxicity at
the dosage as large as 3.2 mg/kg in cynomolgus monkeys and 1.6 mg/kg in mice. The results of dose safety evaluation of
vaccine indicated that the safe dose of the vaccine were higher than 0.375 mg/kg in rats and 3.2 mg/kg in cynomolgus
monkeys. Our work showed the vaccine may be a candidate for a highly effective, cheap, and safe influenza vaccine for use
in humans.
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Introduction
During the period of May through December of 1997, an
outbreak of human influenza A (H5N1) infection in the Hong
Kong of China gave the serious cause for concern [1]. At the time
there was no indication whether human infections would remain
linked to the outbreak of poultry infections or whether H5N1 virus
would acquire the ability to be transmitted from person-to-person
[2]. From January 1 to March 31, 2004, 12 patients were
confirmed to infect H5N1 influenza virus in Thailand [3], Human
infections with influenza A (H5N1) were identified in 10 patients
in Vietnam in January 2004 [4]. Widespread vaccination is the
preferred strategy for preventing or at least limiting potential
pandemic influenza outbreaks. The most expeditious way to
generate H5N1 vaccine was to use the licensed technology, such
as inactivated [5] or attenuated viral vaccines [6]. However, there
are several practical and scientific challenges to the development
of H5N1 vaccines [7]. These include the high pathogenicity of
wild-type H5N1 influenza viruses, reduced yields of candidate
vaccine viruses in the embryos of fertilized hen’s eggs compared to
yields of human influenza viruses, limited manufacturing capacity,
and poor immunogenicity of H5 HA. Despite these obstacles,
several approaches have been used to generate candidate vaccines
and a few have advanced to clinical trials [8]. Clinical trails have
been completed for vaccines. That include inactivated viral
vaccines based on H5N1 viruses isolated in 2004 [9,10] and a
recombinant H5 HA subunit vaccine based on the H5N1 virus
HA gene isolated in 1997, expressed in a baculovirus vector [11].
A subunit H5N1 vaccine based on A/Vietnam/1203/04 H5N1
virus was developed through reverse genetics and was produced
by Sanofi Pasteur. Its effectiveness was assessed in a randomized
trial among healthy adults in the USA [12]. The addition of
MF59 adjuvant substantially boosted immune responses to this
vaccine [13,14]. Hungarian investigators (Omnivest, Budapest)
also reported promising results for an aluminum phosphate
adjuvant whole-virion H5N1 vaccine. A single dose of the vaccine
containing 30 mg of H5 antigen, induced seroconversions, as
determined by haemagglutinin inhibition, in 18 (90%) of 20
recipients [15].
The baculovirus expression vector system (BEVS) was estab-
lished early in the 1980s [16]. At present, two baculovirus systems
have been extensively used: the AcNPV and the BmNPV systems
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3933[17]. Since then a variety of heterologous genes had been
efficiently expressed in BEVS.
Recombination rescue technology employing linear viral DNA
vectors greatly improves the efficiency of creating recombinant
viruses. Using this method, Possee et al developed a linear AcNPV
expression vector (BacPAK6) that had recombinant efficiency of
over 80% [18]. To generate a recombinant strain of BmNPV
virus, BmBacPAK6, we co-transfected BmN cells with BacPAK6
and BmNPV DNA, and used a homologous recombination
method that increased the frequency of recombinant virus
production to 100% [19]. Currently, we have successfully
expressed several bioactive recombinant proteins using the
BmBacPAK6 expression system and B. mori pupae as a bioreactor.
In addition, we have carried out a large-scale expression and
purification of recombinant hGM-CSF in B. mori pupae and
developed a new approach to the oral administration of these
recombinant proteins [20].
Lu et al. utilized the baculovirus display system to construct a
recombinant baculovirus displaying HA of the avian influenza
virus (AIV) on the viral surface, imparting hemagglutination
activity to the recombinant virus. Intramuscular injection of the
purified HA-displaying baculovirus into a mouse, stimulated the
production of antibodies that inhibited hemagglutination activity
and neutralized influenza viral infections [21]. In a subsequent
study, Yang et al. concluded that the gp64 cytoplasmic domain
(CTD) resulted in highly efficient HA incorporation into the
baculovirus envelope [22]. Foot-and-mouth disease virus (FMDV)
site A, which is crucial to FMDV infections, was fused with the
gp64 and displayed on the surface of baculovirus by Tami et al.
Immunization of the mice with the recombinant baculovirus
expressing the gp64-site A fusion protein elicited positive ELISA
results and high seroneutralizing titers (SNT) against FMDV [23].
To evaluate the baculovirus display system as a vaccine vehicle,
Yoshida et al. generated a recombinant baculovirus (AcNPV-
CSPsurf) system. That displayed the rodent malaria plasmodium
berghei circumsporozoite protein (PbCSP) on the viral surface as a
fusion protein with the baculovirus envelope glycoprotein gp64.
Immunization with adjuvant-free AcNPV-CSPsurf virions induced
high levels of antibodies against PbCSP and protected 60% of the
mice against a sporozoite challenge [24].
We constructed recombinant baculovirus Bmgp64HA, which
contained a gp64HA fusion gene under a control of a polyhedron
promoter. The gp64HA fusion gene contained a synthetic HA
fragment of H5N1 virus fused to the portions of the gp64 gene that
encodes the signal peptide and the transmembrane domain,
allowing display of highly expressed HA on the surface of the
baculovirus envelope. The content of HA protein in the
recombinant virus was 3% of the total baculovirus proteins.
Evaluation of the vaccine in the mice and monkeys suggested that
the vaccine was safe. Mice and monkeys immunized with this
recombinant virus induced production of neutralizing antibodies,
which provided protection against H5N1 infections.
Materials and Methods
Recombinant Virus
The recombinant baculovirus Bmgp64HA was kindly provided
by Professor Chen J.G. of Peking University, as shown in Fig. 1.
Based on the HA sequence of the Hangzhou strain of influenza
virus A/Zhejiang/16/06(H5N1), we constructed a fusion gene
containing a HA gene fragment without both signal peptide and
transmembrane domain. The fragment was inserted the in-frame
with a sequence encoding the B.mori baculovirus gp64 signal
peptide and transmembrane domain. This fusion gene was used to
generate the recombinant baculovirus Bmgp64HA via a homol-
ogous recombination.
Separation and purification of the recombinant
baculovirus
BmN cells were infected with Bmgp64HA at an MOI of 10
infection indexes to generate the amplified recombinant virus used
to infect B. mori pupae by a pinprick inoculation at a density of
1610
6 pfu/strip. The pupae were collected 5 to 7 days after
infection, homogenized, and centrifuged at 12,000 rpm for
30 min. The supernatant was collected and HA bioactivity was
determined using the HA assay. The expression of the gp64HA
fusion protein in the pupae was identified by both SDS-PAGE and
western blotting.
The recombinant Bmgp64HA was separated and purified as
described as below: (1) Pupae infected with Bmgp64HA virus were
homogenized in 0.85% NaCl. The pupae homogenates were
centrifuged in following steps at 3,000 rpm for 30 min, 6,000 rpm
for 30 min, 12,000 rpm for 60 min, and 18,000 rpm for 60 min at
4uC. The supernatant was ultracentrifuged at 30,000 rpm for
40 min at 4uC to precipitate viral particles. The viral pellet was
resuspended in a sterile solution (0.05 M PB, 0.5 M NaCl,
0.04%EDTA). To further purify the viral particles, the suspension
was used in a sucrose density gradient ultracentrifugation. (2)
Sucrose was dissolved in a solution containing 0.05 M PB, 0.5 M
NaCl, and 0.04% EDTA. The density gradient was layered as
follows: the first layer contained a sterile solution (0.05 M
phosphate buffer (PB), 0.5 M NaCl, 0.04% EDTA); the second
layer the sample; the third layer 20% sucrose; the fourth layer 30%
sucrose; and the fifth layer the 52% sucrose solutions to fill the
centrifuge bottle. After a 3-h centrifugation at 35,000 rpm,
samples were collected in sterile tubes. The sucrose solution in
the samples was removed by using a 750 kD hollow filter
cartridge. (3) The sample bioactivity was determined using a
hemagglutination (HA) assay. (4) The samples with high bioactivity
were freeze-dried. That power was resuspended with Al(OH)3
Figure 1. An ideograph of HA/gp64-fusion recombinant
baculovirus
doi:10.1371/journal.pone.0003933.g001
H5N1 Influenza Vaccine
PLoS ONE | www.plosone.org 2 December 2008 | Volume 3 | Issue 12 | e3933adjuvant in 0.9% NaCl (V/V=1:9). The prepared solution was
used as H5N1 influenza vaccine.
Vaccine protection against viral challenge in rhesus
monkeys
The vaccine trial was approved by the Institutional Animal
Care and Use Committee (IACUC) of Institute of Laboratory
Animal Sciences, Chinese Academy of Medical Science (The
approved No.: N-07-6001). The trial complied with the institu-
tional guidelines of the animal welfare and husbandry for
monkeys. Measures were taken to avoid or ameliorate the
suffering of the monkeys, which include both anesthesia and
euthanasia. The studies were performed in accord with the
predetermined study design and objectives.
Twenty rhesus monkeys including 10 females and 10 males
were 3 to 4 years old and weighed 3.5 to 5.0 kg. Beijing Xie’rxin
Biological Resources Institute supplied the experimental animals
that were maintained appropriately prior to viral challenge and
under Biosafe P3 level conditions after challenge. Those monkeys
were randomly divided into 5 groups, including 2 control groups
of Al(OH)3 adjuvant control (CN1) and 0.9% NaCl solvent control
(CN2). Those in the other groups were immunized with either a
high-dose (TA), a medium-dose (TB), or a low-dose (TC) of the
vaccine. There were no significant differences in the weights of
animals in the above various groups.
The doses administered (1 ml each) contained either 2 mg/kg
of the vaccine (TA); 0.67 mg/kg of the vaccine (TB); 0.22 mg/kg
of the vaccine (TC); Al(OH)3 adjuvant in 0.9% NaCl (CN1); or
0.9% NaCl (CN2). Each animal received 2 cervical 0.5 ml
subcutaneous injections, simulating the clinical method of
administration. Those animals were immunized once every 2
weeks; the immunization frequency was determined in accord with
neutralizing antibody titer levels. When the neutralizing antibody
titers reached their highest levels the animals were challenged with
virus (1610
6 pfu in a 1 ml solution) by a nasal drip.
The antibody titers were determined after the first immuniza-
tion. Those animals were challenged with the influenza virus when
antibody titers reached their highest levels and the animals were
euthanized on Day 7 and Day 14 post-challenges. The viral strain
used in challenges was A/tiger/harbin/01/2002(H5N1). The
vaccine protection was evaluated by examining animals for clinical
symptoms, body temperature, blood biochemistry, blood routine,
and histopathological lesions. Those animals were also assayed for
viral genomes by RT-PCR, and neutralizing antibodies, ELISA
methods, viral isolations. The virus in throat swabs on Days 2, 5, 7,
14 post-challenge and lung tissues in necropsy was detected by
RT-PCR. Serum samples were collected and inactivated at 56uC
for 30 min after 2 weeks of a post vaccination and on Days 2, 5, 7,
14 post-challenges. The mixture of sera by a 2-fold dilution and
the standard virus was added to MDCK cells in the microplate.
Cytopathic effects were observed after 3–4 days of culture in 37uC.
The titers of neutralizing antibody were recorded. The antibody
titers were measured by ELISAs with the inactive influenza virus
as the ELISA antigens.
Safety evaluation of vaccine in mice and cynomolgus
monkeys
The Experimental Animals Center of Zhejiang province
supplied 100 males and 100 females ICR mice at the weights of
19 to 21 g. The mice were inoculated with the high-dose, TA of
16 mg/kg, the medium-dose, TB of 8 mg/kg or the low-dose, TC
of 4 mg/kg of the vaccine. The solvent control group was injected
with a 5 ml/kg dose of Al(OH)3 adjuvant in 0.9% NaCl (V/
V=1:9), and the negative control group was injected with a 5 ml/
kg dose of 0.9% sodium chloride. Dosages were prepared in a
solvent by isochoric suspension for use in subcutaneous injections.
The effect of vaccination on the nervous system was surveyed.
Suzhou Xishan Zhongke Experimental Animals Ltd Co.
supplied 10 males and 10 females, 3 to 4 years old, cynomolgus
monkeys at 2.5 to 3.0 kg each. The monkeys were inoculated with
the high-dose, TA of 3.2 mg/kg, the medium-dose, TB of 1.6 mg/
kg or the low-dose, TC of 0.8 mg/kg of the vaccine. The solvent
control group was injected with a 1 ml/kg dose of Al(OH)3
adjuvant in 0.9% NaCl (V/V=1:9), and the negative control
group was injected with a 1 ml/kg dose of 0.9% NaCl. The effect
of vaccination on cardiovascular systemrespiratory system was
surveyed.
Dose safety evaluation in rats and cynomolgus monkeys
The SD rats was vaccinated 8 times every 10 days by a
subcutaneous injection. Three of 5 groups were vaccinated with
9.4, 1.88, 0.375 mg/kg/injection of the vaccine, respectively. Two
of the 5 groups were injected with a solvent control and 0.9%NaCl
1 ml/kg/injection,respectively.
Cynomolgus monkeys were vaccinated 8 times every 10 days by
a subcutaneous injection. Three of 5 groups were vaccinated with
3.2, 1.6, 0.8 mg/kg/injection of the vaccine, respectively. Two of
the 5 group were injected with a solvent control and 0.9%NaCl
1 ml/kg/injection,respectively. Toxic reactions of the vaccine to
rats and cynomolgus monkeys were monitored.
Results
Expression by Bmgp64HA in Bombyx mori pupae
Both SDS-PAGE and western blotting analyses revealed a
45 kD gp64HA fusion protein was expressed in the pupae (Fig. 2).
The proteins of 270 mg purified from recombinant baculovirus
were separated by a 2-D electrophoresis. The silver staining of the
2-D gel (Fig. 3) followed by MALDI-TOF-TOF analysis revealed
the 45 kD gp64HA protein. The gp64HA fusion protein was
approximately 3% of the total protein of Bmgp64HA determined
by a TLC scanner, (CS-9301PC, Shimadzu). The yield rate of
recombinant virus was 1 mg/B. mori pupae.
Figure 2. The expression of a 45 kD HA protein of influenza by
recombinant Bmgp64HA. The recombinant baculovirus was purified
from pupae by four steps centrifugation. Lane M. Protein molecular
weight marker. Lane 1. The purified recombinant baculovirus. Lane 3.
HA protein expression detected by western blotting.
doi:10.1371/journal.pone.0003933.g002
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rhesus monkeys
Antibody titers were determined by ELISA after 2 weeks of post
immunization. After the initial immunization, the antibody titers
of one monkey in the high-dose (TA) group and one monkey in the
medium-dose (TB) group were observed as high as 1:20; the
antibody titers of 2 monkeys in the low-dose (TC) group were also
1:20; the rest of the monkeys were seronegative.
AfterthefirstboosterimmunizationintheTAgroup,theantibody
titer of one previously seronegative monkey (No.031275) was 1:80,
and the antibody titer of another previously seronegative monkey
(No. 031869)was1:20;theantibodytiterofonemonkey(No. 040152)
changed from1:20 to 1:40. In the TB group, the antibody titer of the
previously seronegative monkey (No.040193) was 1:80 after the first
booster immunization and the antibody titer of another monkey
(No.040278) increased to1:80 while the other monkeys in the TB
group,remainedseronegative.IntheTCgroup,theantibodytiterof2
monkeys changed from1:20 to 1:40. The antibody titers of other two
monkeys in the TC group were 1:20, 1:80, respectively.
After the second booster immunization, most of monkeys
maintained neutralizing antibody titers at their previous levels.
However, 2 previously seronegative monkeys in the medium-dose
group produced antibody titers of 1:20 and 1:40, respectively. The
antibody titers of the rhesus monkeys as measured by ELISA were
shown in Table 1.
Protective immunity induced by vaccine in rhesus
monkeys
Neutralizing antibody titers reached their highest levels after
animals were inoculated with the vaccine for 3 times. No abnormal
clinical responses were observed during the virus challenge, and
bodytemperaturesand the indexes ofblood biochemistryand blood
routine remained in the normal range after the viral challenge.
A histopathological examination revealed the 2 monkeys had a
severe interstitial pneumonia and other 2 monkeys had a moderate
to severe interstitial pneumonia in the control group. All monkeys
in TA group had a mild interstitial pneumonia, and 4 monkeys in
TB group had a mild to moderate interstitial pneumonia. All of the
animals in both TA and TB groups were protected from the
interstitial pneumonia by the vaccine. In the TC group, one
monkey had a mild to moderate interstitial pneumonia, and other
3 monkeys had a moderate to severe interstitial pneumonia.
RT-PCR results in rhesus monkeys after viral challenge
RT-PCR was used to detect H5N1 virus in tissues of rhesus
monkeys after the viral challenge. Using throat swab samples from
two monkeys, virus was detected in each of the dose groups (TA,
TB, TC) after 2 days of the viral challenge. One monkey in the
control group was observed positive. After 5 days of the viral
challenge, virus was not detected in any of the monkeys. Lungs of
two monkeys in the control group were observed viral positive
after 7 days after the viral challenge; and one monkey in each
vaccine dose group was also positive. Fourteen days of the viral
challenge, all of lung tissues were tested viral negative. These
results are shown in Table 2.
Neutralizing antibody titers in rhesus monkeys after viral
challenge
In vaccinated rhesus monkeys, neutralizing antibodies were
determined at Days 0, 2, 5, 7, and 14 after the viral challenge. The
results were shown in Table 3. The neutralizing antibody levels
declined transiently after the viral challenge. In 6 of the monkeys,
the neutralizing antibody titer had decreased after 2 days of the
viral challenge. However the neutralizing antibody titers of 1:8 or
1:4 were observed in two monkeys that were previously
seronegative after 7 days of the viral challenge. The neutralizing
antibody titers reached 1:8 in 7 of 12 monkeys, 1:4 in 3of 12
monkeys, and negative in 2 of 12 monkeys. By the contrast, the
titer of 1:4 was observed in 2 of 4 monkeys in the control group.
Virus isolation after challenge in rhesus monkeys
After the viral challenge, viral genomes were detected by means
of RT-PCR in throat swab samples of one monkey in the TB
group. No virus was detected in samples of the monkeys in either
TA or TC groups after 2 days of the viral challenge while all of the
monkeys in the control group were viral positive. No virus was
detected in the monkeys of the control group after 5, 7, or 14 days
of the viral challenge. After 7 days of the viral challenge, virus was
Figure 3. The ecombinant baculovirus Bmgp64HA was detect-
ed by 2-D electrophoresis. 45 kD HA protein was expressed in
recombinant baculovirus.
doi:10.1371/journal.pone.0003933.g003
Table 1. The antibody titers of the rhesus monkeys were measured by ELISA.
Group First vaccination Second vaccination Third vaccination
Antibody titer 0 1:20 0 1:20 1:40 1:80 0 1:20 1:40 1:80
TA 3/4 1/4 1/4 1/4 1/4 1/4 1/4 1/4 1/4 1/4
TB 3/4 1/4 2/4 - 1/4 1/4 - 1/4 3/4 -
TC 2/4 2/4 - 1/4 2/4 1/4 - 1/4 1/4 2/4
CN 4/4 - 4/4 - - - 4/4 - - -
The numbers of seropositive monkeys were shown.
Each of the groups had 4 monkeys.
doi:10.1371/journal.pone.0003933.t001
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monkey from the control group, respectively.
Safety evaluation of vaccine in mice and cynomolgus
monkeys
The results of the general behavior, locomotor activity,
subthreshold hypnotic dosage, sodium pentobarbital cooperative
experiment and rotating coordination function assay showed
that no singnificant effects on the nervous system of the mice
was observed after administration of the influenza vaccine by
the subcutaneous injection with 16, 8, 4 mg/kg, solvent 5 ml/
kg.
Examinations on the cardiovascular and respiratory system in
cynomolgus monkey showed that each of indexes was not
influenced markedly by inoculation of influenza vaccine in 3.2,
1.6,0.8 mg/kg and solvent 1 ml/kg dose. No significant effects on
the monkeys were observed in the blood pressure, respiratory
frequency and amplitude electrocardio parameter after the
vaccination (P.0.05). Also the vaccine showed no apparent effect
on body temperature, and means temperature on each time point
after immunization (P.0.05) as compared to the control group.
The similar results were observed in the monkeys, which the
vaccine had no effects on the monkey’s body temperature,
cardiovascular and respiratory system.
Dose safety evaluation of vaccine in rats and cynomolgus
monkeys
The SD rats was vaccinated eight times by the subcutaneous
injection. Granuloma nodules observed at the injection site
gradually were diminished after discontinuation of the inocula-
tions. There was no obvious change in the blood parameters,
organ weight, liver index, spleen weight, and other parameters.
The toxic effect was observed in spleen; however, the effects were
reversible. The toxic reactions were observed after inoculation
with vaccine dose of 1.88 mg/kg, while no toxic reactions
observed after the inoculation with a vaccine dose of 0.375 mg/
kg. The primary toxic reactions of scabs and red patches at the
injection site were observed in the monkeys inoculated with the
vaccine of a a 640-fold dose refered to the human clinical dose.
The reactions were probably caused by the deposition of vaccine
protein and aluminum hydroxide adjuvant in the subcutaneous
tissue. No obvious toxic reaction was observed in other organs of
the monkeys.
Cynomolgus monkeys were inoculated with the vaccine by
subcutaneous injection 8 times with a dose of 3.2, 1.6, or 0.8 mg/
kg in solution (1 ml/kg), or with the solution alone. No long-term
weight change was observed in the monkeys immunized with the
vaccine (Fig. 4). The safe dose of the vaccine was observed to be
higher than 3.2 mg/kg.
Anti-AIV HA antibody titers of the vaccinated monkeys were
maintained for 3 months and increased gradually, reaching their
highest plateau after the fifth immunization, which no any
significant changes were observed between anti-HA antibody
titers and the vaccine dose administered to the monkeys (Fig. 5).
One month after the eighth immunization, serum HA antibody
Table 3. Summary of neutralizing antibody titers of monkey
following viral challenge after immunization.
CN TA TB TC
0 day Seropositive
number
2/4 3/4 2/4
Titer range 1:8 1:4–1:8 1:4
2 day Seropositive
number
2/4 1/4 1/4
Titer range 1:4 1:4 1:4
5 day Seropositive
number
1/4 0/4 1/4
Titer range 1:4 1:4
7 day Seropositive
number
2/4 4/4 3/4 3/4
Titer range 1:4 1:4 1:4–1:8 1:4–1:8
14 day Seropositive
number
2/4 2/4 2/4 2/4
Titer range 1:8 1:16 1:8–1:16 1:8
Each of the groups had 4 monkeys.
doi:10.1371/journal.pone.0003933.t003
Table 2. Summary of RT-PCR results for viral detection in
throat swab samples of monkeys following viral challenge
after immunization with the vaccine.
Group 2 d 5 d 7 d 14 d
TA 2/4 0/4 0/4 0/4
TB 2/4 0/4 0/4 0/4
TC 2/4 0/4 1/4 0/4
CN 1/4 0/4 2/4 0/4
Each of the groups had 4 monkeys.
doi:10.1371/journal.pone.0003933.t002
Figure 4. The weight change in a long-term experiment in monkeys immunized with the influenza vaccine. ‘21’ refers to 1 week before
the vaccine immunization. Vaccine immunizations occurred during weeks 1 to 10. Weeks ‘11 to 14’ refered to the time post-immunization.
doi:10.1371/journal.pone.0003933.g004
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highest level. HA antibody titers of the monkeys in the solvent
control and 0.9% NaCl control groups were not affected by the
vaccination.
Discussion
Both Influenza A and B viruses spread in human nearly every
winter in temperate regions of both the Northern and Southern
hemispheres and throughout the year in tropical climates [25].
The impact of annual influenza epidemics are difficult to assess
due to its co-circulation with other agents that have adverse
respiratory impacts. The nonspecific illnesses are also associated
with influenza infection, the available estimates of the impact of
influenza are nevertheless impressive. As reported 6,200 to
29,000 people died of each of the epidemics occurred between
1975 and 1976, and 1984 and 1990 [26] in England and Wales,
and average of 51,203 people died annually during influenza
outbreaks in the United States between 1976 and 1999 [27].
Three percent of the local population died during an influenza
outbreak in Madagascar in 2002 [28]. Large increases in
absenteeism from schools and works, and increased hospital
admissions and consultations with general practitioners occur
during influenza outbreaks.
A vaccine providing 40 to 50% protection against the human
H5N1 influenza was developed in 2007 [29]. Additionally, a new
avian influenza vaccine, providing up to 70% protection of the
human population, was reported [30]. In comparison, seasonal
vaccinations provide protection against influenza to approximately
90% of healthy young people [31]. The clinically effective dose of
avian influenza vaccine for human is typically 10 to 90 mg [29,30].
There are three types of influenza vaccines including whole
virus vaccines, split vaccines, and subunit vaccines. Because the
vaccine production requires viral replication, which is risky in that
virus from the production facility could escape and possibly
disseminate into the human population. Alternatively, the use of
chick embryos to generate vaccines against H5 viruses could be
challenging because influenza viruses grown for vaccine produc-
tion are lethal to the embryos [32]. To date, the various
technologies used to produce vaccines showed to be inefficient
[33,34]. The use of genetic engineering technologies to create
vaccines rather than conventional methods of using inactivated
live virus may increase production efficiencies and decrease the
possibility of the viral spreading into the population.
Significant efforts have been made toward developing effective
human influenza vaccines [35,36]. Mary et al. developed a
replication-incompetent, human adenoviral-vector-based, hemag-
glutinin subtype H5 influenza vaccine (HAd-H5HA) that induces
both humoral and cell-mediated immune responses against avian
H5N1 influenza viruses isolated from people [37]. Immunization
with the HAd-H5HA vaccine induced the effective protection in
mice from the disease, death, and primary viral replication
(P,0.01) caused by antigenically distinct strains of H5N1
influenza viruses [38,39].
Recently, a novel eukaryotic surface display system based on a
deep understanding of the construction and function of the
baculovirus genome has been developed. John et al. used an
AcNPV expression system that expressed H5 HA to immunize
human [11]. Their results suggested that baculovirus-expressed
H5 HA induces the production of neutralizing antibodies in
human. An innovative monitoring assay for the recombinant HA
expression and a rapid purification process has also been reported
[40]. Researchers utilized the AcNPV system to express H5, H7,
and H9 subtype hemagglutinins as vaccines to protect against
lethal influenza infections. Lu et al. used AcNPV a surface display
expression of the hemagglutinin of H5N1 influenza virus to
immunize mice. The intramuscular injection of the purified HA-
displaying AcNPV into mice induced the production of neutral-
izing antibodies [21]. Baculovirus infected insect cells release
budding virus from the cells into the intercellular space.
The gp64, the most abundant glycoprotein in type I budding
baculovirus including AcMNPV and BmNPV and forms trimers
through disulfide crosslinking on the surface of the baculovirus,
can mediate the viral infection of cells [41]. The BmNPV gp64
signal peptide is located in the N-terminal region and its
transmembrane domain in the C-terminal of the protein,. By
fusing exogenous peptides to these portions of the gp64 protein,
they can be displayed on the viral envelope surface. At present,
peptides derived from several eukaryotic proteins have been
expressed on the baculovirus surface. These are limited to the
AcNPV expression systems of the Sf cell line, but it is not yet
suitable for a large scale of manufacturing.
Our laboratory has developed B. mori pupae as a bioreactor
system for highly efficient expression of hGM-CSF [20]. We have
also constructed a linearized BmNPV expression system, BmBac-
PAK6 [42] expressing a fusion gene including the HA gene of
H5N1 (Hangzhou strain) [43] which is inserted the in-frame with
the sequence that encodes the BmNPV gp64 signal peptide and
transmembrane domain to create baculovirus Bmgp64HA. The
fusion gene expresses a high level of the 45 kD gp64HA fusion
protein. We were able to isolate pure Bmgp64HA from infected
pupae. The yield was 1 mg per B. mori pupae. The HA content of
the total viral protein was measured at approximately 3%. This
system may provide a fundamental platform for the large-scale
vaccine production.
We used the recombinant Bmgp64HA to vaccinate rhesus
monkeys against H5N1 influenza virus. The results showed that in
the rhesus monkeys, inoculated with 2 mg/kg, 0.67 mg/kg,
0.22 mg/kg of vaccine after three vaccinations, could induce the
production of over 1:40 antibody titers in 50%, 67%, or 67% of
the monkeys, respectively.
We have successfully constructed a baculovirus surface display
system. One example of this surface display system is the
recombinant Bmgp64HA virus, which efficiently displays the
H5N1 influenza virus HA on the baculovirus envelope surface.
This recombinant virus can be used as a safe and effective vaccine
Figure 5. Anti-HA antibody titers of the vaccinated monkeys in
a long-term experiment.
doi:10.1371/journal.pone.0003933.g005
H5N1 Influenza Vaccine
PLoS ONE | www.plosone.org 6 December 2008 | Volume 3 | Issue 12 | e3933against H5N1 infection in monkeys. Our recombinant virus
provides a highly efficient, cost effective, and safe influenza
vaccine. And our improved baculovirus display system could be
used for the production of other types of vaccines.
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